Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Oct 12;11(1):20195.
doi: 10.1038/s41598-021-99786-9.

Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan

Yu-Ching Weng  1 , Hsiu J Ho  2 , Yi-Ling Chang  1 , Yun-Ting Chang  3   4 , Chun-Ying Wu  5   6   7   8   9 , Yi-Ju Chen  10   11
Affiliations
Comparative Study

Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan

Yu-Ching Weng et al. Sci Rep. .

Abstract

The relationship between cancer and vitiligo has been explored but with inconsistent results. To examine the long-term cancer risk in vitiligo patients, we conducted a retrospective nationwide cohort study. From the National Health Insurance Research Database of Taiwan, a total of 13,824 vitiligo patients were identified and matched with 55,296 reference subjects without vitiligo by age, gender, and propensity score estimated by major comorbidities from 1997 to 2013. Demographic characteristics and comorbidities were compared between these two groups. Incidence rate ratios and hazard ratios (HRs) were calculated to examine cancer risks. The 16-year incidence rates of overall cancers were 621.06 (566.56-675.55) and 726.99 (697.24-756.74) per 100,000 person-years in the vitiligo and reference groups. Patients with vitiligo showed a significantly decreased risk of overall cancers [adjusted HR, 0.85; 95% confidence interval (CI), 0.77 to 0.93, p < 0.001] compared with reference subjects without vitiligo after adjusting for age, sex, comorbidities, and treatments. The risks of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) were significantly reduced (adjusted HR 0.21, 95% CI 0.11-0.38, p < 0.001), as well as internal malignancies (adjusted HR 0.89, 95% CI 0.81-0.99, p = 0.026). The results were consistent across different subgroups of patients, including male gender, ages more than 40 years, and those receiving long-term systemic disease-modifying antirheumatic drugs and phototherapies. Information related to phenotype, disease duration, vitiligo lesion sites, family history of vitiligo or cancer, occupation, and personal lifestyle was not included in the database. Vitiligo is associated with reduced risks of BCC and SCC, as well as internal malignancies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Selection process for subjects in vitiligo and control cohorts.
See this image and copyright information in PMC

References

    1. Silverberg NB. The epidemiology of vitiligo. Curr. Dermatol. Rep. 2015;4:36–43. doi: 10.1007/s13671-014-0098-6. - DOI
    1. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group New discoveries in the pathogenesis and classification of vitiligo. J. Am. Acad. Dermatol. 2017;77(1):1–13. doi: 10.1016/j.jaad.2016.10.048. - DOI - PubMed
    1. Michelsen D. The Double Strike Hypothesis of the vitiligo pathomechanism: New approaches to vitiligo and melanoma. Med. Hypotheses. 2010;74(1):67–70. doi: 10.1016/j.mehy.2009.08.008. - DOI - PubMed
    1. Speeckaert R, van Geel N. Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo. Exp. Dermatol. 2017;26(7):630–634. doi: 10.1111/exd.13069. - DOI - PubMed
    1. Failla CM, Carbone ML, Fortes C, Pagnanelli G, Dtri S. Melanoma and vitiligo: In good company. Int. J. Mol. Sci. 2019;20(22):5731. doi: 10.3390/ijms20225731. - DOI - PMC - PubMed

Publication types